Carbon-11-PF 06809247

Drug Profile

Carbon-11-PF 06809247

Alternative Names: [11C]PF-06809247

Latest Information Update: 12 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Inflammation

Most Recent Events

  • 10 Mar 2017 Pfizer completes a phase I trial for Neuroinflammation (Diagnosis) in USA (IV) (NCT03100136)
  • 16 Nov 2016 Phase-I clinical trials in Inflammation (Diagnosis) in USA (IV) (NCT03100136)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top